Berinert SC Injection Holds Promise as “First Choice” for HAE Attacks: CSL Japan Chief

CSL Behring Japan President Jean-Marc Morange Jean-Marc Morange, president of CSL Behring Japan, is confident that the firm’s subcutaneous injection version of Berinert (human C1 inactivator), released last month, is on course to become the “first choice” drug among prophylactic...read more